Form 4: Director Daniel Spiegelman Receives Maze Therapeutics Grant

Director Daniel Spiegelman was granted 18,000 stock options in Maze Therapeutics, Inc. as part of a standard equity incentive.

Summary

• Director Daniel K. Spiegelman was granted 18,000 stock options to purchase common stock in Maze Therapeutics, Inc.
• The options have an exercise price of $23.58 per share.
• The grant is subject to a one-year vesting schedule, becoming fully exercisable on the earlier of the 2027 annual stockholders meeting or June 8, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of Maze Therapeutics common stock exceeding the $23.58 strike price.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector, intended to incentivize long-term oversight and strategic alignment.

Comparison to Industry Standards

• The one-year vesting period is consistent with standard director compensation practices for mid-cap biotechnology firms.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 8, 2027, or the 2027 annual stockholders meeting.

Key Dates

Keywords

Maze Therapeutics, MAZE, Form 4, Insider Trading, Stock Options, Director Compensation